Dakota Wealth Management Buys 24,610 Shares of Abbott Laboratories $ABT

Dakota Wealth Management increased its stake in shares of Abbott Laboratories (NYSE:ABT) by 13.8% in the 3rd quarter, Holdings Channel reports. The firm owned 202,797 shares of the healthcare product maker’s stock after buying an additional 24,610 shares during the period. Dakota Wealth Management’s holdings in Abbott Laboratories were worth $27,163,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the company. Cloud Capital Management LLC purchased a new stake in shares of Abbott Laboratories during the 3rd quarter valued at about $29,000. Guerra Advisors Inc bought a new stake in shares of Abbott Laboratories during the 3rd quarter valued at $31,000. Anfield Capital Management LLC lifted its position in shares of Abbott Laboratories by 81.3% in the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock valued at $32,000 after acquiring an additional 104 shares in the last quarter. Delos Wealth Advisors LLC bought a new position in shares of Abbott Laboratories in the second quarter worth about $32,000. Finally, Bridge Generations Wealth Management LLC purchased a new stake in shares of Abbott Laboratories during the third quarter worth about $33,000. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Trading Up 2.6%

ABT opened at $115.14 on Tuesday. Abbott Laboratories has a 12 month low of $105.27 and a 12 month high of $141.23. The stock has a fifty day moving average price of $118.19 and a 200-day moving average price of $125.68. The firm has a market cap of $200.20 billion, a price-to-earnings ratio of 30.95, a PEG ratio of 1.79 and a beta of 0.75. The company has a current ratio of 1.70, a quick ratio of 1.24 and a debt-to-equity ratio of 0.23.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting analysts’ consensus estimates of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The business had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. During the same period in the previous year, the company posted $1.34 earnings per share. The firm’s revenue was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, equities research analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories’s payout ratio is currently 67.74%.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on ABT shares. William Blair raised shares of Abbott Laboratories to a “strong-buy” rating in a report on Thursday, November 20th. Leerink Partners lowered their price objective on Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating for the company in a research note on Friday, January 30th. Piper Sandler cut their price target on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a report on Friday, January 23rd. The Goldman Sachs Group cut their price target on shares of Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating on the stock in a report on Friday, January 23rd. Finally, BTIG Research dropped their price objective on Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating on the stock in a research note on Tuesday, February 17th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $137.05.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Q4 results and forward guidance: Abbott reported Q4 EPS roughly in line with expectations while revenue was slightly below consensus, but management set FY‑2026 EPS guidance (5.55–5.80) that sits above recent analyst forecasts — a catalyst for investor optimism around underlying margin recovery and recurring businesses. Abbott (ABT) Reports Q4 Earnings: What Key Metrics Have to Say
• Positive Sentiment: Dividend support: Abbott declared a quarterly dividend of $0.63 per share (ex‑dividend Apr 15), reinforcing the stock’s income profile and making the shares more attractive to yield-focused investors.
• Positive Sentiment: Analyst backing and price targets: The stock has multiple buy/overweight ratings and a recent median price target near $140, which provides visible upside support versus the current level and can attract momentum buyers. Abbott Laboratories Stock (ABT) Opinions on Exact Sciences Acquisition
• Neutral Sentiment: Acquisition financing and strategic repositioning: Abbott is arranging large debt financing (reported $20B bond sale) to fund the Exact Sciences acquisition — investors see strategic rationale (expands oncology/diagnostics) but are weighing integration execution and incremental leverage. Abbott Laboratories Stock (ABT) Opinions on Exact Sciences Acquisition
• Negative Sentiment: Product‑safety litigation risk: A wrongful‑death lawsuit alleges defects in the FreeStyle Libre 3/3 Plus glucose monitors and links the devices to multiple deaths and injuries; this raises potential regulatory, recall and settlement risk that could pressure sentiment if litigation expands. Wrongful Death Suit Tests Abbott Libre 3 And Exact Sciences Ambitions

Insider Activity

In other Abbott Laboratories news, Director Daniel J. Starks acquired 10,000 shares of the firm’s stock in a transaction dated Wednesday, February 4th. The stock was purchased at an average price of $108.73 per share, for a total transaction of $1,087,300.00. Following the acquisition, the director owned 6,738,817 shares in the company, valued at approximately $732,711,572.41. This trade represents a 0.15% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.